Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2. 2021

Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
Key Lab of Vaccine, Prevention and Control of Infectious Disease of Zhejiang Province, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310015, China.

The novel coronavirus pneumonia (COVID-19) pandemic is a great threat to human society and now is still spreading. Although several vaccines have been authorized for emergency use, only one recombinant subunit vaccine has been permitted for widespread use. More subunit vaccines for COVID-19 should be developed in the future. The receptor binding domain (RBD), located at the S protein of SARS-CoV-2, contains most of the neutralizing epitopes. However, the immunogenicity of RBD monomers is not strong enough. In this study, we fused the RBD-monomer with a modified Fc fragment of human IgG1 to form an RBD-Fc fusion protein. The recombinant vaccine candidate based on the RBD-Fc protein could induce high levels of IgG and neutralizing antibody in mice, and these could last for at least three months. The secretion of IFN-γ, IL-2 and IL-10 in the RBD-stimulated splenocytes of immunized mice also increased significantly. Our results first showed that the RBD-Fc vaccine could induce both humoral and cellular immune responses and might be an optional strategy to control COVID-19.

UI MeSH Term Description Entries
D007141 Immunoglobulin Fc Fragments Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN. Fc Fragment,Fc Fragments,Fc Immunoglobulin,Fc Immunoglobulins,Ig Fc Fragments,Immunoglobulin Fc Fragment,Immunoglobulins, Fc,Immunoglobulins, Fc Fragment,Fc Fragment Immunoglobulins,Fc Fragment, Immunoglobulin,Fc Fragments, Ig,Fc Fragments, Immunoglobulin,Fragment Immunoglobulins, Fc,Fragment, Fc,Fragments, Ig Fc,Immunoglobulin, Fc
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072417 Protein Domains Discrete protein structural units that may fold independently of the rest of the protein and have their own functions. Peptide Domain,Protein Domain,Domain, Peptide,Domain, Protein,Domains, Peptide,Domains, Protein,Peptide Domains
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
March 2023, Vaccines,
Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
December 2020, Signal transduction and targeted therapy,
Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
September 2023, NPJ vaccines,
Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
May 2024, European journal of microbiology & immunology,
Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
January 2022, Advanced healthcare materials,
Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
April 2021, Vaccine,
Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
February 2021, Journal of medical virology,
Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
January 2024, Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,
Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
October 2022, Vaccines,
Yi-Sheng Sun, and Jing-Jing Zhou, and Han-Ping Zhu, and Fang Xu, and Wen-Bin Zhao, and Hang-Jing Lu, and Zhen Wang, and Shu-Qing Chen, and Ping-Ping Yao, and Jian-Min Jiang, and Zhan Zhou
January 2023, Frontiers in bioengineering and biotechnology,
Copied contents to your clipboard!